Neurocrine Biosciences | NBIX - Operating Profit


Neurocrine Biosciences reported $214.6M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
ALKERMES USD -48.28M 37.33M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Exelixis USD 251.34M 15.43M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Prothena USD -27.21M 12.55M Dec/2025
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Repligen USD 19.98M 13K Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Teva Pharmaceutical Industries USD 758M 271M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xoma USD -15.64M 5.56M Sep/2024